ATEL Ventures Portfolio Company, Adenosine Therapeutics to be Acquired by Clinical...

ATEL Ventures Portfolio Company, Adenosine Therapeutics to be Acquired by Clinical Data, Inc.

SAN FRANCISCO--(Business Wire)--
ATEL Ventures, a leading provider of secured financing to emerging
growth companies, is pleased to announce that Clinical Data, Inc. has
entered into an agreement to acquire Adenosine Therapeutics, an ATEL
portfolio company. Clinical Data (Nasdaq:CLDA) paid $11 million in
cash, and entered into a $22 million, five-year promissory note and a
separate $3.2 million, 32-month promissory note to acquire the
privately held Adenosine. Adenosine also stands to receive up to $30
million more in cash upon the achievement of certain regulatory and
commercial milestones.

Adenosine Therapeutics has been leading the way in the discovery
and development of adenosine receptor selective drug candidates since
1999. ATEL Venture's 4.5 million debt and equity financing package
that was provided in 2007 helped support the further development of
Adenosine's portfolio of products that aim to improve the lives of
patients suffering from a wide range of diseases.

"Adenosine's outstanding track record in pharmaceutical
development and research collaboration made it a compelling investment
choice," said Steve Rea, Executive Vice President at ATEL Ventures, a
division of ATEL Capital Group. "We congratulate Adenosine on its
acquisition and the future opportunities it will bring to the
company."

About ATEL Ventures

Since its founding in 1977, San Francisco-based ATEL Capital Group
has become the largest private and closely-held independent leasing
company in the United States, with approximately $2 billion in
asset-secured transactions under management. ATEL Capital formed ATEL
Ventures, Inc. to provide working capital and equipment financing term
loans to emerging growth companies in information technology, life
sciences, specialty retail and alternative energy. For information
about ATEL Ventures, contact Steven Rea, executive vice president, or
visit their website at www.atel.com/ventures.

About Adenosine Therapeutics

Adenosine Therapeutics is a world leader in the development of
novel pharmaceutical products that target adenosine receptor subtypes.
The company's most advanced product is Apadenoson, a highly selective
A2A agonist, which is in Phase III clinical development for use as a
stress agent during cardiac imaging. The Company is also developing
drugs for the treatment of asthma, diabetes, Parkinson's disease,
cancer, ophthalmic disease and inflammatory indications such as
sepsis, heart attack, ischemia-reperfusion injury, sickle cell crisis,
vascular injury, arthritis, spinal cord injury, COPD, and inflammatory
bowel disease. For more information on Adenosine Therapeutics, please
visit our web site at www.adenrx.com.

About Clinical Data, Inc.

Clinical Data is a global biotechnology company unlocking the
potential of molecular discovery, From Targeted Science to Better
Healthcare(TM). Its PGxHealth(R) division focuses on proprietary
biomarker and pharmacogenetic test development as well as targeted
therapeutics to help predict drug safety and efficacy, thereby
reducing health care costs and improving clinical outcomes. Its
Cogenics(R) division provides genomics services to both research and
regulated environments. Through these divisions, Clinical Data is
leveraging advances in molecular discovery to provide tangible
benefits for patients, doctors, scientists and health plans worldwide.
Visit the company's website at www.clda.com for more information.

ATEL Ventures, Inc.
Steve Rea, 415-616-3436
Executive Vice President
srea@atel.com

Copyright Business Wire 2008